• 1
    Butterworth RF. Pathogenesis and treatment of portal-systemic encephalopathy: an update. Dig Dis Sci 1992; 37: 3217.
  • 2
    Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39: 73945.
  • 3
    Conn HBJ. Hepatic Encephalopathy: Syndromes and Therapies. Bloomington, Illinois: Medi-Ed Press, 1994.
  • 4
    Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 54959.
  • 5
    Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double blind, randomized trial. Gastroenterology 2003; 124: 1792801.
  • 6
    Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 70513.
  • 7
    Hayashi M, Ohnishi H, Kawade Y, Muto Y, Takahashi Y. Augmented utilization of branched-chain amino acids by skeletal muscle in decompensated liver cirrhosis in special relation to ammonia detoxication. Gastroenterol Jpn 1981; 16: 6470.
  • 8
    Horst D, Grace ND, Conn HO, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984; 4: 27987.
  • 9
    Van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991; 100: 11148.
  • 10
    Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996; 23: 108492.
  • 11
    Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 1984; 2: 4935.
  • 12
    Grüngreiff K, Presser HJ, Franke D, et al. Correlations between zinc, amino acids and ammonia in liver cirrhosis. Z Gastroenterol 1989; 27: 7315.
  • 13
    Dejong CH, Deutz NE, Soeters PB. Muscle ammonia and glutamine exchange during chronic liver insufficiency in the rat. J Hepatol 1994; 21: 299307.
  • 14
    Rabbani P, Prasad A. Plasma ammonia and liver ornithine transcarbamoylase activity in zinc-deficient rats. Am J Physiol 1978; 235: E2036.
  • 15
    Yoshida Y, Higashi T, Nouso K, et al. Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama 2001; 55: 34955.
  • 16
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 6939.
  • 17
    Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 71621.
  • 18
    Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 57383.
  • 19
    Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22: 54150.
  • 20
    Lezak MD. A compendium of tests and assessment techniques. In: LezakMD, ed. Neuropsychological Assessment. New York: Oxford University Press, 1995: 3814.
  • 21
    Kato A, Kato M, Ishii H, et al. Development of quantitative neuropsychological tests for diagnosis of subclinical hepatic encephalopathy in liver cirrhosis patients and establishment of diagnostic criteria-multicenter collaborative study in Japanese. Hepatol Res 2004; 30: 718.
  • 22
    Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998; 51: 104553.
  • 23
    Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998; 51: 103744.
  • 24
    Marchesini G, Bianchi G, Amodio P, et al. Italian Study Group for quality of life incirrhosis. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 1708.
  • 25
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 26
    Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51: 90312.
  • 27
    Dawson B, Trapp R. Basic and Clinical Biostatistics. 4th ed. USA: McGraw Hill, 2004.
  • 28
    Hayashi M, Ikezawa K, Ono A, et al. Evaluation of the effects of combination therapy with branched-chain amino acid and zinc supplements on nitrogen metabolism in liver cirrhosis. Hepatol Res 2007; 37: 6159.
  • 29
    Katayama K. Ammonia metabolism and hepatic encephalopathy. Hepatol Res 2004; 30S: 7380.
  • 30
    Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 14104.
  • 31
    Dhiman RK, Sawhney MS, Chawla YK, et al. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000; 45: 154952.
  • 32
    Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 107181.
  • 33
    Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48: 16226.
  • 34
    Younossi ZM, Boparai N, Price LL, et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001; 96: 2199205.
    Direct Link:
  • 35
    Saab S, Ibrahim AB, Shpaner A, et al. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl 2005; 11: 21823.
  • 36
    Kalaitzakis E, Josefsson A, Bjornsson E. Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. BMC Gastroenterol 2008; 8: 46.
  • 37
    Moriwaki H, Miwa Y, Tajika M, et al. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 2004; 313: 4059.
  • 38
    Hara K, Yonezawa K, Weng QP, et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273: 1448494.
  • 39
    Sano H, Furuta S, Toyama S, et al. Study on the metabolic fate of catena-(S)-[mu-[N alpha-(3-aminopropionyl)histidinato(2-)-N1,N2,O:N tau]-zinc]. 1st communication:absorption, distribution, metabolism and excretion after single administration to rats. Arzneimittelforschung 1991; 41: 96575.
  • 40
    Nishimura Y, Yamagishi Y, Ando K, Saito T, Matsukura T. L-Carnosine and close derivatives accelerate zinc uptake from the intestine in rats. Biomedical Res Trace Elements 2001; 12: 15967.
  • 41
    Nagamine T, Takagi H, Takayama H, et al. Preliminary study of combination therapy with interferon-α and zinc in chronic hepatitis C patients with genotype 1b. Biol Trace Elem Res 2000; 75: 5363.
  • 42
    Younossi ZM, Grryatt G, Kiwi M, Moparai N, King D. Development of a disease-specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295300.
  • 43
    Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991; 36: 12048.
  • 44
    Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med 1993; 2: 4146.